1. Home >
  2. M&A >
  3. Add-on Acquisition >
  4. United States >
  5. New York >
  6. Mesoblast Acquires Angioblast Systems

M&A Deal Summary

Mesoblast Acquires Angioblast Systems

On December 7, 2010, Mesoblast acquired life science company Angioblast Systems

Acquisition Highlights
  • This is Mesoblast’s 1st transaction in the Life Science sector.
  • This is Mesoblast’s 1st transaction in the United States.
  • This is Mesoblast’s 1st transaction in New York.

M&A Deal Summary
Date 2010-12-07
Target Angioblast Systems
Sector Life Science
Buyer(s) Mesoblast
Deal Type Add-on Acquisition

Target

Angioblast Systems

New York, New York, United States
Angioblast Systems, Inc. is a biotechnology company. Angioblast is a provider in the development and commercialization of novel therapeutic products for the treatment of cardiovascular diseases.

Search 214,238 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Mesoblast

Melbourne, Australia
Category Company
Founded 2004
Sector Life Science
Employees81
Revenue 17M USD (2025)
DESCRIPTION

Mesoblast is a biotherapeutics company with proprietary cell-based and protein technologies. Mesoblast’s technology platforms have the potential to deliver a diverse portfolio of clinical-stage products to treat major conditions with unmet medical needs. Mesoblast was founded in 2004 and is based in Melbourne, Australia.

DEAL STATS #
Overall 1 of 2
Sector: Life Science M&A 1 of 2
Type: Add-on Acquisition M&A Deals 1 of 1
State: New York M&A 1 of 1
Country: United States M&A 1 of 2
Year: 2010 M&A 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2013-10-10 Osiris Therapeutics - Mesenchymal Stem Cell Business

Columbia, Maryland, United States

Osiris Therapeutics's Mesenchymal Stem Cell (MSC) Business is a manufacturer of stem cells.

Buy -
Mergr

Solution for

Product

Company

Legal